Entrectinib Impresses in Certain Lung Cancers

(MedPage Today) -- A majority of patients with advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC) obtained durable remissions with the ROS1 inhibitor entrectinib (Rozlytrek), according to an updated integrated analysis...